|
Indian Journal of Dermatology, Venereology and Leprology
Medknow Publications on behalf of The Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)
ISSN: 0378-6323 EISSN: 0973-3922
Vol. 69, Num. 3, 2003, pp. 252-254
|
Indian Journal of Dermatology, Venereology & Leprology, Vol. 69, No.
3, May-June, 2003, pp. 252-254
Letter to Editor
Comments on "Serological study for sexually transmitted
diseases in
patients attending Std clinics in Calcutta"
Sunil Dogra, Bhushan Kumar
Address for correspondence: Dr. Bhushan Kumar, Prof. and Head, Department
of Dermatology Veneorology and Leprology, PGIMER, Chandigarh-160012, India.
E-mail: kumarbhushan@hotmail.com
Code Number: dv03024
Sir,
It was interesting reading "Serological study for sexually
transmitted diseases in patients attending STD clinics
in Calcutta" published in Indian J Dermatol Venereol Leprol 2002; 68 275-278.
We have some queries:
comments for the authors to address.
What was the purpose of doing a qualitative VDRL test (which
is more relevant in field conditions) in such a reputed institute of serology?
A test with undiluted serum can result in false negativity because of the prozone
phenomenon. Any titre cannot be considered significant (reactive). The VDRL
test always has a standard cut off value for the uniform interpretation of
results. However, the authors have not mentioned any such value in their article.
In a developing country like India, various chronic infections can result in
a false positive VDRL test in 1-3% of the patients. Further, a `reactive' non-treponemal
test indicates a present infection or a recently treated or untreated infection.1 The
result needs to be correlated with the medical history, examination and even
with specific treponemal tests.
TPHA is a quantitative test reported in titre and so agglutination
at a particular titre is more meaningful than mere agglutination. It is well
known that a low degree of TPHA positivity will remain for years even in cases
who have been adequately treated.2 VDRL and TPHA tests indicate
the same disease and adding them up falsely increases the total number of positive
tests without any logical basis.
Serologic assays may be useful in detecting the prevalence
of Chlamydia trachomatis infections of the genital tract in the community.
Since 45-65% of patients may have IgG antibodies resulting from past infection,
only a certain level of titre or demonstration of a four-fold rise in titre
in a repeat sample is meaningful. Detection of IgM antibodies is more helpful
in establishing acute chlamydia infections of the genital tract.3 The
present test report does not make us any wiser.
The results section is confusing; tabulating one or more serological
tests in various combinations does not give any meaningful information. The
article does not give us any idea about what the authors want to convey -single
sample seropositivity without any cut off value?
It is commendable that the authors have tried to study the
serum sample of such a large number of STD clinic attendees. However, a better-designed
and interpreted study would have resulted in more useful information especially
coming from such a leading centre. We hope our comments will be taken in the
spirit they are meant to be.
References
- Ray K, et al. Screening and confirmation of syphilis by
serology _ a five years experience. Ind J Sex Transm Dis 1991;12:47-50.
- Young H. Syphilis-Serology Dermatol Clin 1998;16:691-198.
- MA Chernesky. Chlamydia trachomatis diagnostics.
Sex Transm Inf 2002;78:232-4.
Response by the author
Sir,
With reference to the queries of Dr. Dogra and Dr. Kumar on
our article "Serological study for sexually transmitted diseases in patients
attending STD clinics in Calcutta", our comments on the various points
raised by them are as follows:
- As had been clearly mentioned in the Introduction,
one of the main objectives of the study was "to ascertain the prevalence
of syphilis, hepatitis B, chlamydia and HIV infection among patients attending
different STD clinics in Calcutta".
- Since the VDRL test is a low cost, rapid and
a good screening test, all the samples were first subjected to qualitative
tests and samples showing reactivity were then further subjected to a quantitative
test. In fact, it has been clearly mentioned in the article, under Materials
and Methods that "Quantitative test was performed on all reactive sera
including those showing weak or rough reaction". Moreover, all the VDRL
reactive sera, including all biological false positive sera were subjected
to the TPHA test, which is a very specific test.
- As mentioned under Materials and Methods, the TPHA test
was performed using TPHA 200 kits, manufactured by Newmarket Laboratories
Ltd., UK, strictly as per the manufacturer's instructions. If one goes through
the
literature of the kit in detail, it will be observed that the final dilution
of the sample is 1:80. Hence this is again a quantitative test and not
qualitative. This is the standard
method for the TPHA test.
- About the comment that adding up VDRL and TPHA tests "falsely
increases total number of positive tests without any logical basis",
it appears that the data has been misinterpreted. It must be clarified that
Table
V showing two tests positive, i.e. VDRL+TPHA, indicates that the same sample
was positive for both VDRL as well as TPHA. So there is no question of increasing
the total number.
- Yes, we agree that IgM antibodies are more helpful
in establishing acute chlamydia infections of the genital tract, but the
present study was undertaken more from the epidemiological point of view.
The values
obtained from this assay are intended to be an aid for diagnosis only.
- Table II clearly shows positivity for different serological
tests among different age groups, infection being most commonly observed
in the 15-30 years age group (20.13%), followed by the 30-45 years age
group (12.69%) and the > 45 years age group (4.38%). It thus shows that
the 15-30 years age group is the most vulnerable, and because of their risky
behavior, this age group is susceptible to multiple infections.
- Single sample positivity proves that only one infection
was positive. All the serological tests, viz. HBsAg, TPHA, chlamydia-IgG,
were done by kits, as per the manufacturers' instructions and guidelines.
The HIV
test was done at the School of Tropical Medicine, which is a NACO centre
for HIV detection. All the sera were tested by the ELISA method, using kits
from
INNOTEST HIV-1/HIV-2 Sp. Innogentics N.V., Belgium. ELISA reactives
sera were confirmed
by the Western Blot test, using kits
from Innogentics N.V., Belgium.
- As we all know, without a cut off value no ELISA
test is positive and the HBsAg, chlamydia and HIV tests are
all ELISA tests. The TPHA test uses a dilution of 1:80 sample, which is a
very specific test for syphilis. Cut off values are essential for any ELISA
test
and have been duly considered. As is well
known, results cannot be calculated without a
cut off value.
- The Institute of Serology is the pioneer, Institute for
the production of VDRL antigen. This institute initiated the production of
cardiolipin antigen for serological tests of syphilis, with the assistance
of WHO, in 1954. For the present study also, the methodology used was of
a high standard and by using kits of highly reputed manufacturers, as indicated.
Gopi Thawani
Address for correspondence: Dr.(Mrs.) Gopi Thawani, Institute of Serology,
3 Kyd Street, Kolkata-700016
Copyright 2003 - Indian Journal of Dermatology, Venereology & Leprology.
Free full text also available from: http://www.ijdvl.com
|